Get started
Author

Hanns‐Christian Mahler

Observed names: H.- C. Mahler, H.-C. Mahler, Hanns-Christian Mahler, Hanns-christian Mahler, Hanns-christian mahler, Mahler, Hanns-Christian 1972-
Observed institutions: Goethe University Frankfurt, F. Hoffmann-La Roche AG, University of Freiburg, Merck KGaA, Darmstadt (Germany), University of Basel, Johannes Gutenberg University Mainz, Lonza (Switzerland)
ORCID: 0000-0002-2427-6795
Observed ORCID: 0000-0002-2427-6795
OpenAlex ID: A5052151636
Protein aggregation: Pathways, induction factors and analysis
2008 · Hanns-Christian Mahler, Wolfgang Friess, et al. · Journal of Pharmaceutical Sciences · 941
PDF
Shaken, Not Stirred: Mechanical Stress Testing of an IgG1 Antibody
2008 · Sylvia Kiese, Astrid Papppenberger, et al. · Journal of Pharmaceutical Sciences · 407
An Industry Perspective on the Monitoring of Subvisible Particles as a Quality Attribute for Protein Therapeutics
2010 · Satish K. Singh, Nataliya Afonina, et al. · Journal of Pharmaceutical Sciences · 339
Induction and analysis of aggregates in a liquid IgG1-antibody formulation
2005 · Hanns-Christian Mahler, Robert Müller, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 320
Key interactions of surfactants in therapeutic protein formulations: A review
2015 · Tarik A. Khan, Hanns-Christian Mahler, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 305
The Degradation of Polysorbates 20 and 80 and its Potential Impact on the Stability of Biotherapeutics
2011 · Ravuri S. K. Kishore, Sylvia Kiese, et al. · Pharmaceutical Research · 305
Degradation of Polysorbates 20 and 80: Studies on Thermal Autoxidation and Hydrolysis
2010 · Ravuri S.K. Kishore, Astrid Pappenberger, et al. · Journal of Pharmaceutical Sciences · 291
PDF
Forced Degradation of Therapeutic Proteins
2011 · Andrea Hawe, Michael Wiggenhorn, et al. · Journal of Pharmaceutical Sciences · 255
Assessment of Net Charge and Protein–Protein Interactions of Different Monoclonal Antibodies
2011 · Christian Lehermayr, Hanns-Christian Mahler, et al. · Journal of Pharmaceutical Sciences · 215
Subcutaneous Injection Volume of Biopharmaceuticals—Pushing the Boundaries
2016 · Roman Mathaes, Atanas Koulov, et al. · Journal of Pharmaceutical Sciences · 179
Rheological characterization and injection forces of concentrated protein formulations: An alternative predictive model for non-Newtonian solutions
2014 · Andrea Allmendinger, Stefan Fischer, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 136
FTIR and nDSC as Analytical Tools for High-Concentration Protein Formulations
2006 · Susanne Matheus, Wolfgang Friess, et al. · Pharmaceutical Research · 132
Considerations for the Use of Polysorbates in Biopharmaceuticals
2018 · Michael T. Jones, Hanns-Christian Mahler, et al. · Pharmaceutical Research · 129
Freeze drying of human serum albumin (HSA) nanoparticles with different excipients
2008 · Marion G. Anhorn, Hanns-Christian Mahler, et al. · International Journal of Pharmaceutics · 126
Selective Oxidation of Methionine and Tryptophan Residues in a Therapeutic IgG1 Molecule
2015 · Emilien folzer, Katharina diepold, et al. · Journal of Pharmaceutical Sciences · 117
PDF
Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges
2016 · Wim Jiskoot, Grzegorz Kijanka, et al. · Journal of Pharmaceutical Sciences · 115
Surface Activity of a Monoclonal Antibody
2009 · Hanns-Christian Mahler, Frank Senner, et al. · Journal of Pharmaceutical Sciences · 100
If Euhydric and Isotonic Do Not Work, What Are Acceptable pH and Osmolality for Parenteral Drug Dosage Forms?
2016 · Dieter Roethlisberger, Hanns-Christian Mahler, et al. · Journal of Pharmaceutical Sciences · 95
Adsorption Behavior of a Surfactant and a Monoclonal Antibody to Sterilizing-Grade Filters
2010 · Hanns-Christian Mahler, Franziska Huber, et al. · Journal of Pharmaceutical Sciences · 95
Oxidative DNA damage and mutations induced by a polar photosensitizer, Ro19-8022
1999 · Olaf Will, Elmar Gocke, et al. · Mutation Research/DNA Repair · 90
In Vivo Stability of Therapeutic Proteins
2020 · Joachim Schuster, Atanas Koulov, et al. · Pharmaceutical Research · 87
Subvisible (2–100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis
2015 · Vincent Corvari, Linda O. Narhi, et al. · Biologicals · 82
PDF
Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and Strategy
2015 · Linda O. Narhi, Vincent Corvari, et al. · Journal of Pharmaceutical Sciences · 81
Oxidative DNA base damage induced by singlet oxygen and photosensitization: recognition by repair endonucleases and mutagenicity
2000 · Ina Schulz, Hanns-Christian Mahler, et al. · Mutation Research/DNA Repair · 68
Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods
2013 · Tobias Werk, David B. Volkin, et al. · European Journal of Pharmaceutical Sciences · 66
Works count: 142
Citation count: 7,399
H-index: 43
I10-index: 98
Year
Topic
Type